Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 19:00 save search
Global CAR-T Cell Therapy Market Report 2023: Rise in Awareness Regarding CAR T-Cell Therapy Drives Growth
Published: 2023-07-06 (Crawled : 19:00) - prnewswire.com
CRBU | $3.98 -0.25% -0.25% 930K
|
Health Technology
|
| O: 0.32%
H: 25.69%
C: 21.83%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.7%
H: 0.36%
C: -0.76%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.5%
H: 0.14%
C: -1.45%
report t-cell cell global car-t therapy growth market
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-04-03 (Crawled : 19:00) - biospace.com/
SNGX | $0.4012 -1.13% -1.15% 450K
|
Health Technology
|
| O: -3.55%
H: 11.45%
C: 6.32%
fda drug t-cell treatment meeting application
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-03-21 (Crawled : 19:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: -0.48%
yescarta t-cell treatment therapy
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
Published: 2023-02-09 (Crawled : 19:00) - globenewswire.com
IMMX | $2.32 8.92% 8.19% 80K
|
|
| O: -5.14%
H: 4.53%
C: -12.08%
nxc-201 biopharma expansion meeting t-cell trial response
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.14%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
Published: 2022-11-23 (Crawled : 19:00) - biospace.com/
TLSA | News | $0.7501 -0.46% -0.47% 2.5M
|
Health Technology
|
| O: -4.7%
H: 11.48%
C: 6.57%
response foralumab publication
Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
Published: 2022-10-05 (Crawled : 19:00) - prnewswire.com
RGBP | $0.7 5.69% 1.5K
|
Manufacturing
|
| O: 1.54%
H: 6.06%
C: -1.52%
patent car-t cancer
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
ACLX | $54.43 4.67% 4.46% 410K
|
|
| O: -0.31%
H: 1.15%
C: -0.54%
aclx-002 research pre-clinical car-t leukemia therapy cancer preclinical acute myeloid leukemia
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
ABCL | $3.985 -0.62% -0.63% 1.6M
|
|
| O: -0.41%
H: 0.0%
C: -6.9%
platform
BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
Published: 2022-02-21 (Crawled : 19:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.26%
H: 0.81%
C: 0.46%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: -4.75%
H: 3.0%
C: 0.27%
cel collaboration cancer t-cell immunotherapy
Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-Cell Malignancies
Published: 2022-01-07 (Crawled : 19:00) - precisionbiosciences.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
DTIL | $10.33 6.72% 6.29% 31K
|
Health Technology
| Email alert
Add to watchlist
pbcar0191 car-t cel t-cell
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market Report 2021-2026: Competitor Landscape, Opportunity Assessment, Approved Drugs, Drugs Patent, Price and Sales insights
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.18%
H: 0.02%
C: -0.51%
sales drug patent cel therapy t-cell
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
QGEN | $41.89 1.63% 0.0% 900K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $41.89 1.63% 0.0% 900K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2021-01-07 (Crawled : 19:00) - biospace.com/
SNGX | $0.4012 -1.13% -1.15% 450K
|
Health Technology
|
| O: 9.92%
H: 5.56%
C: -0.69%
partnership distribution t-cell treatment
IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
Published: 2020-12-03 (Crawled : 19:00) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
|
| O: 1.14%
H: 4.49%
C: -1.12%
cancer therapy ovarian cancer phase 2 t-cell
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.